Non-Sterile Compounding Education and Resources Now Available
February 5, 2026Training Course for Non-Sterile Compounding Supervisors
Following approval from the Board in March 2024 and in response to operational assessment data showing non-sterile compounding standards in some pharmacies are not being fully met, the College has developed a training course for non-sterile compounding supervisors.
As of February 5, 2026, this training course, which comprises eight modules and one final exam, is mandatory for registrants who are:
- New to the role of non-sterile compounding supervisor
- Current non-sterile compounding supervisors in pharmacies where standards for non-sterile compounding are not being met
The training course is free of charge and also available to anyone (e.g., registrants wishing to refresh, strengthen, or supplement their knowledge). Further information, including who is mandated to take this course, how they will be notified, and how completion of training will be verified, is available on the College’s website.
At this time, there is no other OCP-approved training that meets this specific mandate for non-sterile compounding supervisors. Information on the OCP-approved training mandated for sterile compounding supervisors will be shared in the coming months.
Access the Non-Sterile Compounding Supervisor Training Course
Non-Sterile Compounding Risk Assessment Resources
Risk assessments must be completed for all non-sterile preparations compounded at a pharmacy. To help registrants understand how to appropriately document their risk assessments, including their rationale for the level of requirements and the risk mitigation measures that must be in place, the College has developed the following resources:
- A risk assessment template that outlines important details to document, reference, and consider
- A companion guide to support understanding of what to include in the template and where to find it
- Risk assessment example 1: 1% hydrocortisone powder in 1% clotrimazole cream
- Risk assessment example 2: Progesterone 400 mg suppositories
While use of this template is optional, these resources demonstrate the requirements and expectations for risk assessments as outlined in the NAPRA Model Standards for Pharmacy Compounding of Non-Sterile Preparations.